


Dr. dr. Dewa Ayu Putri Sri Masyeni, SpPD., KPTI., FINASIM.

LEPTOSPIROSIS

Epidemiologi, Mikrobiologi,
dan Manajemen Klinis



LEPTOSPIROSIS

Epidemiologi,

MIKROBIOLOGI, DAN MANAJEMEN KLINIS

Dr.dr. Dewa Ayu Putri Sri Masyeni, SpPD., KPTI., FINASIM.



PENERBIT KBM INDONESIA

Adalah penerbit dengan misi memudahkan proses penerbitan buku
buku penulis di tanah air Indonesia. Serta menjadi media sharing
proses penerbitan buku.

LEPTOSPIROSIS

EPIDEMIOLOGI, MIKROBIOLOGI, DAN MANAJEMEN KLINIS

*Copyright @2026 By Dr.dr. Dewa Ayu Putri Sri Masyeni, SpPD., KPTI., FINASIM.
All right reserved*

Penulis

Dr.dr. Dewa Ayu Putri Sri Masyeni, SpPD., KPTI., FINASIM.

Desain Sampul

Aswan Kreatif

Tata Letak

Nur Kasanah

Editor

Dr. Putu Saraswati Laksmi Dewi, SpPD.

Official

Depok, Sleman-Jogjakarta (Kantor)

Penerbit Karya Bakti Makmur (KBM) Indonesia

Anggota IKAPI/No. IKAPI 279/JTI/2021

081357517526 (Tlpn/WA)

Website

<https://penerbitkbm.com>

www.penerbitbukumurah.com

Email

naskah@penerbitkbm.com

Distributor

<https://penerbitkbm.com/toko-buku/>

Youtube

Penerbit KBM Sastrabook

Instagram

[@penerbit.kbmindonesia](https://www.instagram.com/penerbit.kbmindonesia)

[@penerbitbukujogja](https://www.instagram.com/penerbitbukujogja)

ISBN: 978-634-278-136-4

Cetakan ke-1, Februari 2026

15,5 x 23 cm, iv + 82 halaman

Isi buku diluar tanggungjawab penerbit

Hak cipta merek KBM Indonesia sudah terdaftar di DJKI-Kemenkumham dan isi buku dilindungi undang-undang.

Dilarang keras menerjemahkan, memfotokopi, atau memperbanyak sebagian atau seluruh isi buku ini tanpa seizin penerbit karena beresiko sengketa hukum

**Sanksi Pelanggaran Pasal 113
Undang-Undang No. 28 Tahun 2014 Tentang Hak Cipta**

1. Setiap Orang yang dengan tanpa hak melakukan pelanggaran hak ekonomi sebagaimana dimaksud dalam Pasal 9 ayat (1) huruf i untuk Penggunaan Secara Komersial dipidana dengan pidana penjara paling lama 1 (satu) tahun dan/atau pidana denda paling banyak Rp 100.000.000 (seratus juta rupiah).
2. Setiap Orang yang dengan tanpa hak dan/atau tanpa izin Pencipta atau pemegang Hak Cipta melakukan pelanggaran hak ekonomi Pencipta sebagaimana dimaksud dalam Pasal 9 ayat (1) huruf c, huruf d, huruf f, dan/atau huruf h untuk Penggunaan Secara Komersial dipidana dengan pidana penjara paling lama 3 (tiga) tahun dan/atau pidana denda paling banyak Rp 500.000.000,00 (lima ratus juta rupiah).
3. Setiap Orang yang dengan tanpa hak dan/atau tanpa izin Pencipta atau pemegang Hak Cipta melakukan pelanggaran hak ekonomi Pencipta sebagaimana dimaksud dalam Pasal 9 ayat (1) huruf a, huruf b, huruf e, dan/atau huruf g untuk Penggunaan Secara Komersial dipidana dengan pidana penjara paling lama 4 (empat) tahun dan/atau pidana denda paling banyak Rp 1.000.000.000,00 (satu miliar rupiah).
4. Setiap Orang yang memenuhi unsur sebagaimana dimaksud pada ayat (3) yang dilakukan dalam bentuk pembajakan, dipidana dengan pidana penjara paling lama 10 (sepuluh) tahun dan/atau pidana denda paling banyak Rp 4.000.000.000,00 (empat miliar rupiah).

KATA PENGANTAR

...

Puji syukur kita panjatkan ke hadirat Tuhan Yang Maha Esa, karena dengan rahmat dan karunia-Nya, buku ini dapat diselesaikan. Buku ini berjudul "Leptospirosis: Epidemiologi, Mikrobiologi, dan Manajemen Klinis" ditujukan untuk memberikan pemahaman yang mendalam mengenai leptospirosis, sebuah penyakit zoonosis yang menjadi perhatian global karena dampaknya yang signifikan terhadap kesehatan masyarakat.

Leptospirosis merupakan penyakit yang disebabkan oleh infeksi bakteri *Leptospira spp.*, yang dapat menular dari hewan ke manusia dan sering terjadi di daerah dengan kondisi sanitasi yang buruk. Penyakit ini dapat menimbulkan berbagai gejala, mulai dari yang ringan hingga yang berat, dan sering kali sulit didiagnosis pada tahap awal. Oleh karena itu, pengetahuan yang mendalam tentang epidemiologi, patogenesis, dan manajemen klinis leptospirosis sangat penting bagi para profesional kesehatan.

Buku ini disusun dengan tujuan sebagai referensi bagi dokter, mahasiswa kedokteran, dan peneliti yang tertarik pada bidang penyakit infeksi, khususnya leptospirosis. Dalam buku ini, kami mengupas berbagai aspek terkait leptospirosis, mulai dari sejarah penemuan penyakit ini, epidemiologinya di berbagai belahan dunia, hingga pendekatan diagnostik dan pengobatan yang efektif.

Kami berharap buku ini dapat menjadi sumber informasi yang berguna dan bermanfaat dalam upaya pencegahan dan pengendalian leptospirosis. Terima kasih kepada semua pihak yang telah membantu dalam proses penulisan dan penerbitan buku ini, serta kepada para pembaca yang telah meluangkan waktu untuk mempelajari informasi yang kami sajikan.

Semoga buku ini dapat memberikan kontribusi positif bagi peningkatan pengetahuan dan kesadaran mengenai leptospirosis, sehingga dapat membantu dalam upaya memperbaiki kesehatan masyarakat secara keseluruhan. Selamat membaca!

Bali, 10 Januari 2025

Penulis

DAFTAR ISI

...

KATA PENGANTAR.....	i
DAFTAR ISI.....	iii
BAB 01 PENDAHULUAN.....	1
A. Epidemiologi Leptospirosis.....	1
BAB 02 MIKROBIOLOGI & IMUNOLOGI	7
A. Mikrobiologi	7
B. Immunopatogenesis	12
C. Peran Sitokin, Kemokin Dan Genetik Pada Leptospirosis Berat	15
D. Mekanisme Menghindari Dari Sistem Imun	17
E. Immunopatogenesis Of Leptospirosis Berat (Weils' Disease)	18
F. Peran Mikrobiota Usus Terhadap Keparahan Leptospirosis	24
BAB 03 MANIFESTASI KLINIS	29
BAB 04 PENDEKATAN DIAGNOSIS INFEKSI LEPTOSPIRA.....	39
A. Pemeriksaan Diagnostic Cepat Pada Seting Infeksi Akut.....	41
B. Pemeriksaan Darah Rutin Dan Biomarker	42
C. Pemeriksaan Serologi.....	43
D. Pemeriksaan Kultur	47
E. Pemeriksaan PCR dan Sekuensing	50

BAB 05 MANAGEMEN LEPTOSPIROSIS 57
 A. Modalitas Terapi Kausal..... 61

BAB 06 PENUTUP 63
 A. Highlight..... 63
 B. Kesimpulan 64

DAFTAR PUSTAKA 65

PROFIL PENULIS 81

DAFTAR PUSTAKA

...

1. Harran E, Hilan C, Djelouadji Z, Ayrat F. Epidemiology of Leptospirosis: The First Literature Review of the Neglected Disease in the Middle East. *Trop Med Infect Dis.* 2022;7(10):260. doi:10.3390/tropicalmed7100260
2. Costa F, Hagan JE, Calcagno J, et al. Global Morbidity and Mortality of Leptospirosis: A Systematic Review. Small PLC, ed. *PLoS Negl Trop Dis.* 2015;9(9):e0003898. doi:10.1371/journal.pntd.0003898
3. Torgerson PR, Hagan JE, Costa F, et al. Global Burden of Leptospirosis: Estimated in Terms of Disability Adjusted Life Years. Small PLC, ed. *PLoS Negl Trop Dis.* 2015;9(10):e0004122. doi:10.1371/journal.pntd.0004122
4. Murillo A, Goris M, Ahmed A, Cuenca R, Pastor J. Leptospirosis in cats: Current literature review to guide diagnosis and management. *J Feline Med Surg.* 2020;22(3):216-228. doi:10.1177/1098612X20903601
5. Widjajanti W. Epidemiologi, diagnosis, dan pencegahan Leptospirosis Epidemiology, diagnosis, and prevention of Leptospirosis. *J Heal Epidemiol Commun Diseases.* 2020;5(2):62-68.
6. Thibeaux R, Girault D, Bierque E, et al. Biodiversity of Environmental *Leptospira*: Improving Identification and Revisiting the Diagnosis. *Front Microbiol.* 2018;9. doi:10.3389/fmicb.2018.00816
7. Nakamura S. Measurement of the Cell-Body Rotation of *Leptospira*. In: ; 2020:139-148. doi:10.1007/978-1-0716-0459-5_13

8. Adler B, de la Peña Moctezuma A. *Leptospira* and leptospirosis. *Vet Microbiol.* 2010;140(3-4):287-296. doi:10.1016/j.vetmic.2009.03.012
9. Haake DA, Zückert WR. The Leptospiral Outer Membrane. In: ; 2015:187-221. doi:10.1007/978-3-662-45059-8_8
10. Fraga TR, Barbosa AS, Isaac L. Leptospirosis: Aspects of Innate Immunity, Immunopathogenesis and Immune Evasion From the Complement System. *Scand J Immunol.* 2011;73(5):408-419. doi:10.1111/j.1365-3083.2010.02505.x
11. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. *Cell.* 2006;124(4):783-801. doi:10.1016/j.cell.2006.02.015
12. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. *Nat Rev Microbiol.* 2005;3(1):36-46. doi:10.1038/nrmicro1068
13. Petakh P, Isevykh V, Kamyshnyi A, Oksenykh V. Weil's Disease Immunopathogenesis, Multiple Organ Failure, and Potential Role of Gut Microbiota. *Biomolecules.* 2022;12(12):1830. doi:10.3390/biom12121830
14. Que-Gewirth NLS, Ribeiro AA, Kalb SR, et al. A Methylated Phosphate Group and Four Amide-linked Acyl Chains in *Leptospira interrogans* Lipid A. *J Biol Chem.* 2004;279(24):25420-25429. doi:10.1074/jbc.M400598200
15. Nahori MA, Fournié-Amazouz E, Que-Gewirth NS, et al. Differential TLR Recognition of Leptospiral Lipid A and Lipopolysaccharide in Murine and Human Cells. *J Immunol.* 2005;175(9):6022-6031. doi:10.4049/jimmunol.175.9.6022
16. Geijtenbeek TBH, Van Kooyk Y. Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity. *APMIS.* 2003;111(7-8):698-714. doi:10.1034/j.1600-0463.2003.11107803.x
17. Urban CF, Lourido S, Zychlinsky A. How do microbes evade neutrophil killing? *Cell Microbiol.* 2006;8(11):1687-1696. doi:10.1111/j.1462-5822.2006.00792.x
18. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and

- inflammatory disease. *Biochim Biophys Acta - Mol Cell Res.* 2014;1843(11):2563-2582. doi:10.1016/j.bbamcr.2014.05.014
19. Wink DA, Hines HB, Cheng RYS, et al. Nitric oxide and redox mechanisms in the immune response. *J Leukoc Biol.* 2011;89(6):873-891. doi:10.1189/jlb.1010550
 20. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of the Cytokine Storm. *Microbiol Mol Biol Rev.* 2012;76(1):16-32. doi:10.1128/MMBR.05015-11
 21. Gaudart N, Ekpo P, Pattanapanyasat K, van Kooyk Y, Engering A. *Leptospira interrogans* is recognized through DC-SIGN and induces maturation and cytokine production by human dendritic cells. *FEMS Immunol Med Microbiol.* 2008;53(3):359-367. doi:10.1111/j.1574-695X.2008.00437.x
 22. Yang CW. Leptospirosis renal disease: Understanding the initiation by Toll-like receptors. *Kidney Int.* 2007;72(8):918-925. doi:10.1038/sj.ki.5002393
 23. Zhao H qiang, Li W min, Lu Z qiu, Sheng Z yong, Yao Y ming. The Growing Spectrum of Anti-Inflammatory Interleukins and Their Potential Roles in the Development of Sepsis. *J Interf Cytokine Res.* 2015;35(4):242-251. doi:10.1089/jir.2014.0119
 24. Estavoyer JM, Racadot E, Couetdic G, Leroy J, Grosperin L. Tumor Necrosis Factor in Patients with Leptospirosis. *Clin Infect Dis.* 1991;13(6):1245-1245. doi:10.1093/clinids /13.6. 1245
 25. Mikulski M, Boisier P, Lacassin F, et al. Severity markers in severe leptospirosis: a cohort study. *Eur J Clin Microbiol Infect Dis.* 2015;34(4):687-695. doi:10.1007/s10096-014-2275-8
 26. Reis EAG, Hagan JE, Ribeiro GS, et al. Cytokine Response Signatures in Disease Progression and Development of Severe Clinical Outcomes for Leptospirosis. Coburn J, ed. *PLoS Negl Trop Dis.* 2013;7(9):e2457. doi:10.1371/journal .pntd.0002457
 27. Chirathaworn C, Supputtamongkol Y, Lertmaharit S, Poovorawan Y. Cytokine levels as biomarkers for leptospirosis

- patients. *Cytokine*. 2016;85:80-82. doi:10.1016/j.cyto.2016.06.007
28. Wagenaar JFP, Gasem MH, Goris MGA, et al. Soluble ST2 Levels Are Associated with Bleeding in Patients with Severe Leptospirosis. Peacock SJ, ed. *PLoS Negl Trop Dis*. 2009;3(6):e453. doi:10.1371/journal.pntd.0000453
 29. Fialho RN, Martins L, Pinheiro JP, et al. Role of human leukocyte antigen, killer-cell immunoglobulin-like receptors, and cytokine gene polymorphisms in leptospirosis. *Hum Immunol*. 2009;70(11):915-920. doi:10.1016/j.humimm.2009.08.007
 30. Matsui M, Roche L, Geroult S, et al. Cytokine and Chemokine Expression in Kidneys during Chronic Leptospirosis in Reservoir and Susceptible Animal Models. Wooten RM, ed. *PLoS One*. 2016;11(5):e0156084. doi: 10.1371/journal.pone.0156084
 31. Del Carlo Bernardi F, Ctenas B, da Silva LFF, et al. Immune receptors and adhesion molecules in human pulmonary leptospirosis. *Hum Pathol*. 2012;43(10):1601-1610. doi:10.1016/j.humpath.2011.11.017
 32. Wagenaar JFP, Goris MGA, Gasem MH, et al. Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. *J Infect*. 2009;58(6):425-432. doi:10.1016/j.jinf.2009.04.004
 33. VK C, TY L, WF L, et al. Leptospirosis in human: Biomarkers in host immune responses. *Microbiol Res*. 2018;207:108-115. doi:10.1016/j.micres.2017.11.015
 34. Zhang C, Xu J, Zhang T, et al. Genetic characteristics of pathogenic *Leptospira* in wild small animals and livestock in Jiangxi Province, China, 2002–2015. Lin T, ed. *PLoS Negl Trop Dis*. 2019;13(6):e0007513. doi: 10.1371/journal.pntd.0007513
 35. Esteves LM, Bulhões SM, Branco CC, et al. Human Leptospirosis: Seroreactivity and Genetic Susceptibility in the Population of São Miguel Island (Azores, Portugal). Dellagostin OA, ed. *PLoS One*. 2014;9(9):e108534. doi:10.1371/journal.pone.0108534

36. Cédola M, Chiani Y, Pretre G, Alberdi L, Vanasco B, Gómez RM. Association of Toll-like receptor 2 Arg753Gln and Toll-like receptor 1 Ile602Ser single-nucleotide polymorphisms with leptospirosis in an argentine population. *Acta Trop.* 2015;146:73-80. doi:10.1016/j.actatropica.2015.03.030
37. Murgia R, Garcia R, Cinco M. Leptospire Are Killed In Vitro by Both Oxygen-Dependent and -Independent Reactions. *Infect Immun.* 2002;70(12):7172-7175. doi:10.1128/IAI.70.12.7172-7175.2002
38. Vieira ML, Teixeira AF, Pidde G, et al. *Leptospira interrogans* outer membrane protein LipL21 is a potent inhibitor of neutrophil myeloperoxidase. *Virulence.* 2018;9(1):414-425. doi:10.1080/21505594.2017.1407484
39. Santecchia I, Ferrer MF, Vieira ML, Gómez RM, Werts C. Phagocyte Escape of *Leptospira*: The Role of TLRs and NLRs. *Front Immunol.* 2020;11. doi:10.3389/fimmu.2020.571816
40. Scharrig E, Carestia A, Ferrer MF, et al. Neutrophil Extracellular Traps are Involved in the Innate Immune Response to Infection with *Leptospira*. Vinetz JM, ed. *PLoS Negl Trop Dis.* 2015;9(7):e0003927. doi: 10.1371/journal.pntd.0003927
41. Zipfel PF, Würzner R, Skerka C. Complement evasion of pathogens: Common strategies are shared by diverse organisms. *Mol Immunol.* 2007;44(16):3850-3857. Doi :10.1016/j.molimm.2007.06.149
42. Choy HA. Multiple Activities of LigB Potentiate Virulence of *Leptospira interrogans*: Inhibition of Alternative and Classical Pathways of Complement. Stevenson B, ed. *PLoS One.* 2012;7(7):e41566. doi: 10.1371/journal.pone.0041566
43. Souza NM, Vieira ML, Alves IJ, de Moraes ZM, Vasconcellos SA, Nascimento ALTO. Lsa30, a novel adhesin of *Leptospira interrogans* binds human plasminogen and the complement regulator C4bp. *Microb Pathog.* 2012;53(3-4):125-134. doi:10.1016/j.micpath.2012.06.001
44. Domingos RF, Vieira ML, Romero EC, et al. Features of two proteins of *Leptospira interrogans* with potential role in host-pathogen interactions. *BMC Microbiol.* 2012;12(1):50. doi:10.1186/1471-2180-12-50

45. Barbosa AS, Monaris D, Silva LB, et al. Functional Characterization of LcpA, a Surface-Exposed Protein of *Leptospira* spp. That Binds the Human Complement Regulator C4BP. *Infect Immun.* 2010;78(7):3207-3216. doi:10.1128/IAI.00279-10
46. Yang CW, Wu MS, Pan MJ, Hsieh WJ, Vandewalle A, Huang CC. The *Leptospira* Outer Membrane Protein LipL32 Induces Tubulointerstitial Nephritis-Mediated Gene Expression in Mouse Proximal Tubule Cells. *J Am Soc Nephrol.* 2002;13(8):2037-2045. doi:10.1097/01.ASN.0000022007.91733.62
47. Ondee T, Gillen J, Visitchanakun P, et al. Lipocalin-2 (Lcn-2) Attenuates Polymicrobial Sepsis with LPS Preconditioning (LPS Tolerance) in FcGR1b Deficient Lupus Mice. *Cells.* 2019;8(9):1064. doi:10.3390/cells8091064
48. YANG CW, WU MS, PAN MJ, et al. *Leptospira* Outer Membrane Protein Activates NF- κ B and Downstream Genes Expressed in Medullary Thick Ascending Limb Cells. *J Am Soc Nephrol.* 2000;11(11):2017-2026. doi:10.1681/ASN.V11112017
49. Haake DA, Chao G, Zuerner RL, et al. The Leptospiral Major Outer Membrane Protein LipL32 Is a Lipoprotein Expressed during Mammalian Infection. Orndorff PE, ed. *Infect Immun.* 2000;68(4):2276-2285. doi:10.1128/IAI.68.4.2276-2285.2000
50. Lee SH, Kim KA, Park YG, Seong IW, Kim MJ, Lee YJ. Identification and partial characterization of a novel hemolysin from *Leptospira interrogans* serovar lai. *Gene.* 2000;254(1-2):19-28. doi:10.1016/S0378-1119(00)00293-
51. Li S, Wang M, Ojcius DM, et al. *Leptospira interrogans* infection leads to IL-1 β and IL-18 secretion from a human macrophage cell line through reactive oxygen species and cathepsin B mediated-NLRP3 inflammasome activation. *Microbes Infect.* 2018;20(4):254-260. doi:10.1016/j.micinf.2018.01.010
52. Wang H, Wu Y, Ojcius DM, et al. Leptospiral Hemolysins Induce Proinflammatory Cytokines through Toll-Like Receptor 2-and 4-Mediated JNK and NF- κ B Signaling Pathways. Giambartolomei GH, ed. *PLoS One.* 2012;7(8):e42266. doi:10.1371/journal.pone.0042266

53. Gonçalves-de-Albuquerque CF, Burth P, Silva AR, Younes-Ibrahim M, Castro-Faria-Neto HC, Castro-Faria MV. *Leptospira* and Inflammation. *Mediators Inflamm*. 2012;2012:1-11. doi:10.1155/2012/317950
54. Segura ER, Ganoza CA, Campos K, et al. Clinical Spectrum of Pulmonary Involvement in Leptospirosis in a Region of Endemicity, with Quantification of Leptospiral Burden. *Clin Infect Dis*. 2005;40(3):343-351. doi:10.1086/427110
55. Gouveia EL, Metcalfe J, de Carvalho ALF, et al. Leptospirosis-associated Severe Pulmonary Hemorrhagic Syndrome, Salvador, Brazil. *Emerg Infect Dis*. 2008;14(3):505-508. doi:10.3201/eid1403.071064
56. Bulach DM, Zuerner RL, Wilson P, et al. Genome reduction in *Leptospira borgpetersenii* reflects limited transmission potential. *Proc Natl Acad Sci*. 2006;103(39):14560-14565. doi:10.1073/pnas.0603979103
57. Ren SX, Fu G, Jiang XG, et al. Unique physiological and pathogenic features of *Leptospira interrogans* revealed by whole-genome sequencing. *Nature*. 2003;422(6934):888-893. doi:10.1038/nature01597
58. Silva JJP da, Dalston MO, Carvalho JEM de, Setúbal S, Oliveira JMC de, Pereira MM. Clinicopathological and immunohistochemical features of the severe pulmonary form of leptospirosis. *Rev Soc Bras Med Trop*. 2002;35(4):395-399. doi:10.1590/S0037-8682200200040 0017
59. Seguro AC, Andrade L. Pathophysiology of Leptospirosis. *Shock*. 2013;39(Supplement 1):17-23. doi:10.1097/SHK.0b013e31828fae49
60. Andrade L, Rodrigues AC, Sanches TRC, Souza RB, Seguro AC. Leptospirosis leads to dysregulation of sodium transporters in the kidney and lung. *Am J Physiol Physiol*. 2007;292(2):F586-F592. doi:10.1152/ajprenal.00102.2006
61. Vieira ML, Naudin C, Mörgelin M, Romero EC, Nascimento ALTO, Herwald H. Modulation of Hemostatic and Inflammatory Responses by *Leptospira* Spp. Ricaldi JN, ed. *PLoS Negl Trop Dis*. 2016;10(5):e0004713. doi:10.1371/journal.pntd.0004713

62. Wagenaar JFP, Goris MGA, Partiningrum DL, et al. Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality. *Trop Med Int Heal.* 2010;15(2):152-159. doi:10.1111/j.1365-3156.2009.02434.x
63. Evangelista K, Franco R, Schwab A, Coburn J. *Leptospira interrogans* Binds to Cadherins. Lukehart S, ed. *PLoS Negl Trop Dis.* 2014;8(1):e2672. doi:10.1371/journal.pntd.0002672
64. Kochi LT, Fernandes LGV., Souza GO, et al. The interaction of two novel putative proteins of *Leptospira interrogans* with E-cadherin, plasminogen and complement components with potential role in bacterial infection. *Virulence.* 2019;10(1):734-753. doi:10.1080/21505594.2019. 1650613
65. De Brito T, Silva AMG da, Abreu PAE. Pathology and pathogenesis of human leptospirosis: a commented review. *Rev Inst Med Trop Sao Paulo.* 2018;60. doi:10.1590/s1678-9946201860023
66. Vieira ML, Fernandes LG, Domingos RF, et al. Leptospiral extracellular matrix adhesins as mediators of pathogen-host interactions. *FEMS Microbiol Lett.* 2014;352(2):129-139. doi:10.1111/1574-6968.12349
67. Hobby GP, Karaduta O, Dusio GF, Singh M, Zybaylov BL, Arthur JM. Chronic kidney disease and the gut microbiome. *Am J Physiol Physiol.* 2019;316(6):F1211-F1217. doi:10.1152/ajprenal.00298.2018
68. Al Khodor S, Shatat IF. Gut microbiome and kidney disease: a bidirectional relationship. *Pediatr Nephrol.* 2017;32(6):921-931. doi:10.1007/s00467-016-3392-7
69. Lin CY. Leptospirosis-Associated Acute Kidney Injury. In: *Karger.* ; 2019:20-26. doi:10.1159/000500379
70. Stavropoulou E, Kantartzi K, Tsigalou C, et al. Focus on the Gut-Kidney Axis in Health and Disease. *Front Med.* 2021;7. doi:10.3389/fmed.2020.620102
71. Chou YT, Kan WC, Shiao CC. Acute Kidney Injury and Gut Dysbiosis: A Narrative Review Focus on Pathophysiology and

- Treatment. *Int J Mol Sci.* 2022;23(7):3658. doi:10.3390/ijms23073658
72. Ohtani N, Kawada N. Role of the Gut–Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. *Hepatol Commun.* 2019;3(4):456-470. doi:10.1002/hep4.1331
 73. Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. *J Hepatol.* 2020;72(3):558-577. doi:10.1016/j.jhep.2019.10.003
 74. Zheng Z, Wang B. The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration. *Front Immunol.* 2021;12. doi:10.3389/fimmu.2021.775526
 75. Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. *Front Nutr.* 2021;8. doi:10.3389/fnut.2021.700058
 76. Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. *J Hepatol.* 2020;72(5):1003-1027. doi:10.1016/j.jhep.2020.01.017
 77. Cornell RP, Liljequist BL, Bartizal KF. Depressed Liver Regeneration After Partial Hepatectomy of Germ-Free, Athymic and Lipopolysaccharide-Resistant Mice. *Hepatology.* 1990;11(6):916-922. doi:10.1002/hep.1840110603
 78. Garrett WS. Immune recognition of microbial metabolites. *Nat Rev Immunol.* 2020;20(2):91-92. doi:10.1038/s41577-019-0252-2
 79. Taub R. Liver regeneration: from myth to mechanism. *Nat Rev Mol Cell Biol.* 2004;5(10):836-847. doi:10.1038/nrm1489
 80. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate Enhances Intestinal Epithelial Barrier Function via Up-Regulation of Tight Junction Protein Claudin-1 Transcription. *Dig Dis Sci.* 2012;57(12):3126-3135. doi:10.1007/s10620-012-2259-4
 81. Liu B, Qian J, Wang Q, Wang F, Ma Z, Qiao Y. Butyrate Protects Rat Liver against Total Hepatic Ischemia Reperfusion Injury

- with Bowel Congestion. Bruns H, ed. *PLoS One*. 2014;9(8):e106184. doi:10.1371/journal.pone.0106184
82. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. *Cell Microbiol*. 2018;20(12):e12966. doi:10.1111/cmi.12966
 83. Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. *Mucosal Immunol*. 2019;12(4):843-850. doi:10.1038/s41385-019-0160-6
 84. Taylor SL, Wesselingh S, Rogers GB. Host-microbiome interactions in acute and chronic respiratory infections. *Cell Microbiol*. 2016;18(5):652-662. doi:10.1111/cmi.12589
 85. Gauguet S, D'Ortona S, Ahnger-Pier K, et al. Intestinal Microbiota of Mice Influences Resistance to *Staphylococcus aureus* Pneumonia. McCormick BA, ed. *Infect Immun*. 2015;83(10):4003-4014. doi:10.1128/IAI.00037-15
 86. Bruzzese E, Callegari ML, Raia V, et al. Disrupted Intestinal Microbiota and Intestinal Inflammation in Children with Cystic Fibrosis and Its Restoration with *Lactobacillus GG*: A Randomised Clinical Trial. Bereswill S, ed. *PLoS One*. 2014;9(2):e87796. doi:10.1371/journal.pone.0087796
 87. Ranucci G, Buccigrossi V, Freitas MB de, Guarino A, Giannattasio A. Early-Life Intestine Microbiota and Lung Health in Children. *J Immunol Res*. 2017;2017:1-5. doi:10.1155/2017/8450496
 88. Zhou D, Wang Q, Liu H. Coronavirus disease 2019 and the gut-lung axis. *Int J Infect Dis*. 2021;113:300-307. doi:10.1016/j.ijid.2021.09.013
 89. Xie X, Liu J, Chen X, et al. Gut microbiota involved in leptospiral infections. *ISME J*. 2022;16(3):764-773. doi:10.1038/s41396-021-01122-6
 90. Becattini S, Sorbara MT, Kim SG, et al. Rapid transcriptional and metabolic adaptation of intestinal microbes to host immune activation. *Cell Host Microbe*. 2021;29(3):378-393.e5. doi:10.1016/j.chom.2021.01.003

91. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol.* 2016;16(6):341-352. doi:10.1038/nri.2016.42
92. Akhtar T, Naeem MI, Younus M, Un Nisa Q, Ahmad HM. Dog-mediated Leptospirosis. *Int J Agric Biosci.* 2023;(Zoonosis Volume 4):356-368. doi:10.47278/book.zoon/2023.161
93. Limothai U, Srisawat N, Haake DA. Early Diagnosis and Treatment of Leptospirosis: Optimizing Clinical Outcomes. *J Infect.* 2026:106675. doi:10.1016/j.jinf.2025.106675
94. Haake DA, Levett PN. Leptospirosis in Humans. *Curr Top Microbiol Immunol.* 2015;387:65-97. doi:10.1007/978-3-662-45059-8_5
95. Haake DA, Dundoo M, Cader R, et al. Leptospirosis, Water Sports, and Chemoprophylaxis. *Clin Infect Dis.* 2002;34(9):e40-e43. doi:10.1086/339942
96. Monahan AM, Miller IS, Nally JE. Leptospirosis: risks during recreational activities. *J Appl Microbiol.* 2009;107(3):707-716. doi:10.1111/j.1365-2672.2009.04220.x
97. Kumar SS. Indian Guidelines for the Diagnosis and Management of Human Leptospirosis. In: *The Association of Physicians of India: Mumbai, India.* ; 2013:23-29.
98. World Health Organization. *Human Leptospirosis: guidance for diagnosis, surveillance and control.* Published online 2003.
99. Sykes JE, Reagan KL, Nally JE, Galloway RL, Haake DA. Role of Diagnostics in Epidemiology, Management, Surveillance, and Control of Leptospirosis. *Pathogens.* 2022;11(4):395. doi:10.3390/pathogens11040395
100. Agampodi SB, Matthias MA, Moreno AC, Vinetz JM. Utility of Quantitative Polymerase Chain Reaction in Leptospirosis Diagnosis: Association of Level of Leptospiremia and Clinical Manifestations in Sri Lanka. *Clin Infect Dis.* 2012;54(9):1249-1255. doi:10.1093/cid/cis035
101. Chierakul W, Tientadakul P, Suputtamongkol Y, et al. Activation of the Coagulation Cascade in Patients with Leptospirosis. *Clin Infect Dis.* 2008;46(2):254-260. doi:10.1086/524664

102. Wangrangsimakul T, Althaus T, Mukaka M, et al. Causes of acute undifferentiated fever and the utility of biomarkers in Chiangrai, northern Thailand. Marks F, ed. *PLoS Negl Trop Dis*. 2018;12(5):e0006477. doi:10.1371/journal.pntd.0006477
103. Tillekeratne LG, Suchindran S, Ko ER, et al. Previously Derived Host Gene Expression Classifiers Identify Bacterial and Viral Etiologies of Acute Febrile Respiratory Illness in a South Asian Population. *Open Forum Infect Dis*. 2020;7(6). doi:10.1093/ofid/ofaa194
104. Le Turnier P, Bonifay T, Mosnier E, et al. Usefulness of C-Reactive Protein in Differentiating Acute Leptospirosis and Dengue Fever in French Guiana. *Open Forum Infect Dis*. 2019;6(9). doi:10.1093/ofid/ofz323
105. Crouzet J, Faucher JF, Toubin M, Hoen B, Estavoyer JM. Serum C-reactive protein (CRP) and procalcitonin (PCT) levels and kinetics in patients with leptospirosis. *Eur J Clin Microbiol Infect Dis*. 2011;30(2):299-302. doi:10.1007/s10096-010-1088-7
106. Lindow JC, Wunder EA, Popper SJ, et al. Cathelicidin Insufficiency in Patients with Fatal Leptospirosis. Samuels DS, ed. *PLOS Pathog*. 2016;12(11):e1005943. doi:10.1371/journal.ppat.1005943
107. Murray CK, Gray MR, Mende K, et al. Use of patient-specific *Leptospira* isolates in the diagnosis of leptospirosis employing microscopic agglutination testing (MAT). *Trans R Soc Trop Med Hyg*. 2011;105(4):209-213. doi:10.1016/j.trstmh.2010.12.004
108. Picardeau M, Bertherat E, Jancloes M, Skouloudis AN, Durski K, Hartskeerl RA. Rapid tests for diagnosis of leptospirosis: Current tools and emerging technologies. *Diagn Microbiol Infect Dis*. 2014;78(1):1-8. doi:10.1016/j.diagmicrobio.2013.09.012
109. Lessa-Aquino C, Borges Rodrigues C, Pablo J, et al. Identification of Seroreactive Proteins of *Leptospira interrogans* Serovar Copenhageni Using a High-Density Protein Microarray Approach. Small PLC, ed. *PLoS Negl Trop Dis*. 2013;7(10):e2499. doi:10.1371/journal.pntd.0002499

110. McBride AJA, Cerqueira GM, Suchard MA, et al. Genetic diversity of the Leptospiral immunoglobulin-like (Lig) genes in pathogenic *Leptospira* spp. *Infect Genet Evol.* 2009;9(2):196-205. doi:10.1016/j.meegid.2008.10.012
111. Dawson P, Marfel M, Galloway R, et al. Notes from the Field: Interpretation of Rapid Diagnostic Tests for Leptospirosis During a Dengue Outbreak Yap State, Federated States of Micronesia, 2019. *MMWR Morb Mortal Wkly Rep.* 2020;69(48):1832-1833. doi:10.15585/mmwr.mm6948a6
112. Hornsby RL, Alt DP, Nally JE. Isolation and propagation of leptospires at 37 °C directly from the mammalian host. *Sci Rep.* 2020;10(1):9620. doi:10.1038/s41598-020-66526-4
113. Narkkul U, Thaipadungpanit J, Srilohasin P, et al. Optimization of Culture Protocols to Isolate *Leptospira* spp. from Environmental Water, Field Investigation, and Identification of Factors Associated with the Presence of *Leptospira* spp. in the Environment. *Trop Med Infect Dis.* 2020;5(2):94. doi:10.3390/tropicalmed5020094
114. Zarantonelli L, Suanes A, Meny P, et al. Isolation of pathogenic *Leptospira* strains from naturally infected cattle in Uruguay reveals high serovar diversity, and uncovers a relevant risk for human leptospirosis. Coburn J, ed. *PLoS Negl Trop Dis.* 2018;12(9):e0006694. doi:10.1371/journal.pntd.0006694
115. Miller DA, Wilson MA, Beran GW. The Effect of Storage Time on Isolation of *Leptospira Interrogans* from Bovine Kidneys. *J Vet Diagnostic Investig.* 1990;2(1):63-65. doi:10.1177/104063879000200112
116. Ho HF, Blackmore DK. Effect of chilling and freezing on survival of *Leptospira interrogans* serovar pomona in naturally infected pig kidneys. *N Z Vet J.* 1979;27(6):121-123. doi:10.1080/00480169.1979.34622
117. Cranford HM, Browne AS, LeCount K, et al. Mongooses (*Urva auropunctata*) as reservoir hosts of *Leptospira* species in the United States Virgin Islands, 2019–2020. Neela V kumari, ed. *PLoS Negl Trop Dis.* 2021;15(11):e0009859. doi:10.1371/journal.pntd.0009859
118. Md EM, Vetd FM, Pesenti L, PhD DSM, Md GA, PhD PPM. Clinical aspects of ocular leptospirosis in New Caledonia

- (South Pacific). *Aust N Z J Ophthalmol.* 1999;27(6):380-386. doi:10.1046/j.1440-1606.1999.00269.x
119. Yang B, de Vries SG, Visser BJ, et al. Molecular and antigen detection tests for leptospirosis. *Cochrane Database Syst Rev.* 2015. doi:10.1002/14651858.CD011871
 120. Chiriboga J, Barragan V, Arroyo G, et al. High Prevalence of Intermediate *Leptospira* spp. DNA in Febrile Humans from Urban and Rural Ecuador. *Emerg Infect Dis.* 2015;21(12):2141-2147. doi:10.3201/eid2112.140659
 121. Puche R, Ferrés I, Caraballo L, et al. *Leptospira venezuelensis* sp. nov., a new member of the intermediate group isolated from rodents, cattle and humans. *Int J Syst Evol Microbiol.* 2018;68(2):513-517. doi:10.1099/ijsem.0.002528
 122. Levett PN, Morey RE, Galloway RL, Steigerwalt AG. *Leptospira broomii* sp. nov., isolated from humans with leptospirosis. *Int J Syst Evol Microbiol.* 2006;56(3):671-673. doi:10.1099/ijse.0.63783-0
 123. Vincent AT, Schiettekatte O, Goarant C, et al. Revisiting the taxonomy and evolution of pathogenicity of the genus *Leptospira* through the prism of genomics. Martins EAL, ed. *PLoS Negl Trop Dis.* 2019;13(5):e0007270. doi:10.1371/journal.pntd.0007270
 124. Schürch AC, Arredondo-Alonso S, Willems RJL, Goering RV. Whole genome sequencing options for bacterial strain typing and epidemiologic analysis based on single nucleotide polymorphism versus gene-by-gene-based approaches. *Clin Microbiol Infect.* 2018;24(4):350-354. doi:10.1016/j.cmi.2017.12.016
 125. Guglielmini J, Bourhy P, Schiettekatte O, Zinini F, Brisse S, Picardeau M. Genus-wide *Leptospira* core genome multilocus sequence typing for strain taxonomy and global surveillance. Lin T, ed. *PLoS Negl Trop Dis.* 2019;13(4):e0007374. doi:10.1371/journal.pntd.0007374
 126. Brenner DJ, Kaufmann AF, Sulzer KR, Steigerwalt AG, Rogers FC, Weyant RS. Further determination of DNA relatedness between serogroups and serovars in the family *Leptospiraceae* with a proposal for *Leptospira alexanderi* sp. nov. and four new *Leptospira* genomospecies. *Int J Syst Evol*

- Microbiol.* 1999;49(2):839-858. doi:10.1099/00207713-49-2-839
127. Kmety E, Dikken H. *Classification of the Species Leptospira Interrogans and History of Its Serovars*; 1993.
 128. Fornazari F, Richini-Pereira VB, Joaquim SF, Nachtigall PG, Langoni H. Leptospirosis diagnosis among patients suspected of dengue fever in Brazil. *J Venom Anim Toxins Incl Trop Dis.* 2021;27. doi:10.1590/1678-9199-jvatitd-2020-0118
 129. Ittyachen AM. Covid-19 and leptospirosis: Cytokine storm and the use of steroids. *Trop Doct.* 2021;51(1):128-130. doi:10.1177/0049475520971425
 130. Zaki S, Shieh W. Leptospirosis associated with outbreak of acute febrile illness and pulmonary haemorrhage, Nicaragua, 1995. *Lancet.* 1996;347(9000):535-536.
 131. Romero EC, Billerbeck AEC, Lando VS, Camargo ED, Souza CC, Yasuda PH. Detection of *Leptospira* DNA in Patients with Aseptic Meningitis by PCR. *J Clin Microbiol.* 1998;36(5):1453-1455. doi:10.1128/JCM.36.5.1453-1455. 1998
 132. Wilson MR, Naccache SN, Samayoa E, et al. Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing. *N Engl J Med.* 2014;370(25):2408-2417. doi:10.1056/NEJMoa1401268
 133. Dircio Montes Sergio A, González Figueroa E, María Saadia VG, et al. Leptospirosis Prevalence in Patients with Initial Diagnosis of Dengue. *J Trop Med.* 2012;2012:1-5. doi:10.1155/2012/519701
 134. Nhan TX, Bonnieux E, Rovey C, De Pina JJ, Musso D. Fatal leptospirosis and chikungunya co-infection: Do not forget leptospirosis during chikungunya outbreaks. *IDCases.* 2016;5:12-14. doi:10.1016/j.idcr.2016.06.003
 135. del Valle-Mendoza J, Palomares-Reyes C, Carrillo-Ng H, et al. Leptospirosis in febrile patients with suspected diagnosis of dengue fever. *BMC Res Notes.* 2021;14(1):209. doi:10.1186/s13104-021-05627-3
 136. Niriella MA, Ediriweera DS, De Silva AP, Premarathna BHR, Jayasinghe S, de Silva HJ. Dengue and leptospirosis infection during the coronavirus 2019 outbreak in Sri Lanka. *Trans R*

- Soc Trop Med Hyg.* 2021;115(9):944-946. doi:10.1093/trstmh/trab058
137. Krol P, Coolen-Allou N, Teyseyre L, et al. Differential diagnoses of severe COVID-19 in tropical areas: the experience of Reunion Island. *Trop Med Int Heal.* 2021;26(4):444-452. doi:10.1111/tmi.13542
 138. Conroy AL, Gélvez M, Hawkes M, et al. Host biomarkers distinguish dengue from leptospirosis in Colombia: a case-control study. *BMC Infect Dis.* 2014;14(1):35. doi:10.1186/1471-2334-14-35
 139. Michels M, de Mast Q, Netea MG, et al. Normal Free Interleukin-18 (IL-18) Plasma Levels in Dengue Virus Infection and the Need To Measure Both Total IL-18 and IL-18 Binding Protein Levels. Rosenberg HF, ed. *Clin Vaccine Immunol.* 2015;22(6):650-655. doi:10.1128/CVI.00147-15
 140. Ko ER, Reller ME, Tillekeratne LG, et al. Host-response transcriptional biomarkers accurately discriminate bacterial and viral infections of global relevance. *Sci Rep.* 2023;13(1):22554. doi:10.1038/s41598-023-49734-6
 141. Iglesias-Ussel MD, O'Grady N, Anderson J, et al. A Rapid Host Response Blood Test for Bacterial/Viral Infection Discrimination Using a Portable Molecular Diagnostic Platform. *Open Forum Infect Dis.* 2024;12(1).

PROFIL PENULIS

...

Buku ini ditulis oleh **Dr. Dewa Ayu Putri Sri Masyeni, SpPD., KPTI.**, seorang dosen di Fakultas Kedokteran dan Ilmu Kesehatan Universitas Warmadewa, Bali. Beliau merupakan seorang klinisi yang ahli di bidang Ilmu Penyakit Dalam, dengan fokus khusus pada Penyakit Tropis dan Infeksi.

Pendidikan dan Karir

- Gelar: Dr. dr. Dewa Ayu Putri Sri Masyeni menyelesaikan pendidikan kedokteran dan spesialisasi di bidang Penyakit Dalam, serta mendapatkan sertifikasi dalam Kedokteran Tropis dan Infeksi.
- Pengalaman Klinis: Beliau memiliki pengalaman luas sebagai praktisi klinis, menangani berbagai kasus penyakit tropis dan infeksi, serta memberikan penanganan medis yang berkualitas kepada pasien.

Karya Ilmiah dan Publikasi

- Publikasi: Sejak tahun 2017 hingga Desember 2025, beliau telah menerbitkan lebih dari 55 karya ilmiah di jurnal internasional bereputasi yang terindeks Scopus, serta banyak artikel di jurnal terakreditasi Sinta.
- Buku Ajar: Selain publikasi ilmiah, Dr. Dewa Ayu juga telah menyusun beberapa buku ajar yang digunakan oleh mahasiswa kedokteran, berkontribusi dalam pendidikan medis di Indonesia.

Aktivitas Penelitian dan Hibah

- **Travel Medicine:** Beliau aktif dalam bidang kedokteran wisata (travel medicine) dan telah menulis banyak artikel serta hasil riset di bidang ini.
- **Hibah Penelitian:** Dr. Dewa Ayu telah memperoleh berbagai hibah, termasuk hibah nasional dari Kementerian Pendidikan dan Kebudayaan Riset dan Teknologi Indonesia pada tahun 2017, 2020, 2021, dan 2022, serta hibah internasional dari International Society of Travel Medicine (ISTM) pada tahun 2016 dan 2021.

Peran di Jurnal Ilmiah

- **Reviewer:** Dr. Dewa Ayu sering diundang untuk melakukan review artikel pada jurnal internasional, memberikan kontribusi penting dalam proses evaluasi dan publikasi ilmiah.

Komitmen Sosial

Dr. Dewa Ayu berkomitmen untuk meningkatkan kesadaran masyarakat mengenai penyakit tropis dan infeksi, serta aktif dalam program-program pengabdian masyarakat yang bertujuan untuk meningkatkan kesehatan masyarakat di Indonesia.

Dengan pengalaman dan dedikasi yang tinggi, Dr. Dewa Ayu Putri Sri Masyeni berupaya untuk terus berkontribusi dalam bidang kedokteran, penelitian, dan pendidikan, serta memberikan dampak positif bagi masyarakat dan dunia kesehatan.